Misplaced Pages

Golidocitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 19:59, 23 December 2024 (Add: page, display-authors, pmid, pages, issue, volume, journal, date, title, authors 1-30. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webform). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 19:59, 23 December 2024 by Citation bot (talk | contribs) (Add: page, display-authors, pmid, pages, issue, volume, journal, date, title, authors 1-30. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webform)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Golidocitinib
Clinical data
Trade names高瑞哲
Other namesAZD-4205, AZD4205, JAK1-IN-3
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC25H31N9O2
Molar mass489.584 g·mol

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.


References

  1. Keam, Susan J. (2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
  2. Song, Yuqin; et al. (2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): A single-arm, multinational, phase 2 study". The Lancet Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
  3. Jin, Jie; Zhang, Liling; Zou, Liqun; Li, Zengjun; Wu, Huijing; Zhou, Keshu; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Xiao, Qing; Li, Wenyu; Lin, Lie; Wang, Erhua; Chen, Lijia; Cai, Qingqing (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: